利伐沙班在血栓性疾病中的应用分析

Analysis of Rivaroxaban in Thrombotic Diseases

目的开展利伐沙班在血栓性疾病中的应用调查,总结临床用药经验,规范抗凝管理。方法检索医院合理用药管理系统,2016年1月—2018年12月应用利伐沙班抗凝治疗的住院患者资料,对调查结果进行回顾性统计、分析。结果共纳入患者288例,平均年龄为(71.0±12.0)岁,其中≥65岁患者占72.57%(209/288);给药剂量在5~30mg/d,平均(9.43±3.20)mg/d;利伐沙班主要应用于非瓣膜性房颤和骨科大手术后静脉血栓的预防。结论利伐沙班临床抗凝治疗与预防应用较广泛,其疗效确切,已经为越来越多的患者所认可,但在使用期间仍要密切关注出血性相关不良反应。

Objective To investigate the clinical application of rivaroxaban in thrombotic diseases,and to regulate anticoagulation management.Methods A retrospective analysis was conducted on inpatients who were treated with rivaroxaban in treatment of thrombotic diseases from January 2016 to December 2018 using ipharmacare system,and made a statistical analysis of the survey results.Results A total of 288 patients were enrolled with an average age of(71.0±12.0)years.Patients≥65 years old accounted for 72.57%(209/288).Rivaroxaban was administered at the dose of 5 mg/d to 30 mg/d with an average value of(9.43±3.20)mg/d.Rivaroxaban was mainly used for the prevention of thrombosis in non-valvular atrial fibrillation and orthopedic surgery.Conclusion Rivaroxaban has been widely used in clinical anticoagulant therapy and its curative effect has been confirmed by more and more patients.However,it is still necessary to pay close attention to hemorrhagic-related adverse reactions during use.